Sacubitril Valsartan Sodium Drugs Market Size, Share & Industry Analysis, By Product Type (Originator/Innovator Products, Branded Generics, and Unbranded Generics), By Disease Indication (Heart Failure, Hypertension, and Others), By Formulation (Film-coated Tablets, and Oral Pellets/Granules), By Age Group (Pediatric and Adults), By Treatment Phase (Treatment Initiation, Dose Titration, and Maintenance Therapy), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2026-2034

The sacubitril valsartan sodium drugs market size was valued at USD 8.52 billion in 2025. The market is projected to grow from USD 6.40 billion in 2026 to USD 8.68 billion by 2034, exhibiting a CAGR of 3.87% during the forecast period.

The sacubitril valsartan sodium is a prescription combination medication used to treat chronic heart failure by relaxing blood vessels and reducing fluid buildup. The global market is expected to grow due to rising burden of heart failure and the increasing adoption of guideline-directed therapies for cardiovascular disease. Sacubitril/valsartan therapy is used to reduce the risk of cardiovascular death and hospitalization associated with heart failure, with benefits particularly evident among patients with left ventricular ejection fraction below normal. These clinical advantages, together with increasing physician awareness, broader treatment access, and the rising prevalence of cardiovascular disorders, are supporting the adoption of sacubitril/valsartan drugs across major healthcare markets. Furthermore, the entry of generic formulations is expanding product availability and increasing competition, which is expected to improve patient access to sacubitril/valsartan therapy.

• In August 2025, MSN Pharmaceuticals launched its generic Sacubitril and Valsartan Tablets in the U.S. for reducing the risk of cardiovascular death and hospitalization among adult patients with chronic heart failure and reduced ejection fraction. The launch marked the entry of a lower-cost generic alternative and highlighted the increasing focus of pharmaceutical companies on expanding access to sacubitril/valsartan-based heart failure treatment.

Furthermore, major companies in the industry, such as Novartis AG, Alkem Laboratories Limited, Biocon Limited, and Torrent Pharmaceuticals Limited, are actively participating in strategic collaborations and acquisitions to expand their offerings, facilitate interchangeability, enhance market access, and strengthen their market presence in the healthcare industry.

SACUBITRIL VALSARTAN SODIUM DRUGS MARKET TRENDS

Increasing Generic Entry Reshaping the Brand-Dominated Competitive Landscape is a Key Emerging Trend

The market is witnessing a transition toward multi-manufacturer generic competition, supported by increasing regulatory approvals and commercialization of generic versions of Entresto. Increasing loss-of-exclusivity exposure and the entry of generic manufacturers are starting to alter the competitive landscape. The increasing availability of therapeutically equivalent products is expected to intensify price competition, formulary substitution, and procurement-based switching, while improving treatment affordability and accessibility. Consequently, market growth over the forecast period is expected to become increasingly volume-driven, with market value distributed across a broader base of generic manufacturers rather than remaining concentrated around a single branded product.

• In January 2025, Lupin Limited announced that it received U.S. FDA approval for its generic Sacubitril and Valsartan Tablets in 24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg strengths, referencing Novartis' Entresto. The approval highlights the increasing participation of generic manufacturers in the U.S. sacubitril/valsartan drug sector and the ongoing shift toward a more competitive multi-supplier landscape.

MARKET DYNAMICS

MARKET DRIVERS

Download Free sample to learn more about this report.

Growing Diagnosed Heart-Failure Population and Sustained ARNI Adoption to Propel Market Growth

The expanding diagnosed and treated heart-failure population, coupled with sustained adoption of Angiotensin Receptor-Neprilysin Inhibitor (ARNI) therapy, is one of the key factors driving the sacubitril valsartan sodium drugs market growth. The increasing prevalence of heart failure is being driven by aging populations and the rising burden of underlying cardiovascular risk factors, including hypertension, diabetes, obesity, and coronary artery disease, resulting in a progressively larger pool of patients requiring long-term pharmacological management.

• For instance, in June 2026, the American Heart Association reported that more than 64 billion adults globally are currently living with heart failure, while highlighting that prevalence continues to increase worldwide. Similarly, improved disease screening, updated diagnostic criteria, and greater awareness among healthcare professionals are facilitating earlier identification and treatment of eligible patients.

Consequently, the combination of a growing eligible patient pool and sustained utilization of ARNI-based treatment is expected to support prescription volumes and long-term product demand over the forecast period.

• In May 2025, the American Heart Association announced results from its IMPLEMENT-HF initiative, which demonstrated significant improvements in the use of guideline-directed medical therapy among hospitalized patients with Heart Failure With Reduced Ejection Fraction (HFrEF). The initiative reflects continuing efforts to close treatment gaps and increase the proportion of diagnosed heart-failure patients receiving recommended pharmacological therapies, supporting sustained demand for ARNI treatments such as sacubitril/valsartan.

MARKET RESTRAINTS

Pressure From Generics and Manufacturer’s Exclusivity Loss to Restrict Market Growth

The increasing availability of generic sacubitril/valsartan following loss of exclusivity is expected to restrain value growth of the market. Generic manufacturers generally compete through lower pricing to gain formulary access, procurement contracts, and prescription substitution, resulting in a gradual reduction in the average selling price of sacubitril/valsartan therapies. These factors significantly reduce revenues generated by the originator product. Moreover, substitution of premium-priced branded products with comparatively lower-priced generic formulations can shift a greater proportion of market volume toward products generating substantially lower revenue per prescription. Therefore, although genericization is expected to improve affordability and patient access, rapid price erosion and declining branded-product revenues may limit overall market value expansion during the forecast period.

• In April 2026, Novartis reported that Entresto generated USD 1.31 billion in Q1 2026 sales, declining 42% year-over-year in reported currency and 46% at constant currencies, as generic competition intensified in the U.S. The company stated that U.S. generic erosion more than offset growth from its priority brands, contributing to a 5% decline in overall net sales at constant currencies during the quarter. The sharp decline in Entresto revenue following generic entry demonstrates how loss of exclusivity can rapidly shift prescriptions toward lower-priced alternatives and substantially compress originator revenues, thereby restraining the value growth of the market.

MARKET OPPORTUNITIES

Expanding Generic Penetration in Emerging Markets to Create Significant Growth Opportunities

The expanding penetration of generic sacubitril/valsartan across emerging markets is expected to create significant growth opportunities for market participants. In several developing economies, the large burden of heart failure coexists with relatively lower adoption of advanced guideline-directed therapies, partly due to treatment affordability, limited reimbursement coverage, and high out-of-pocket pharmaceutical expenditure. Increasing availability of competitively priced generic sacubitril/valsartan can substantially reduce treatment costs and enable a broader proportion of eligible heart-failure patients to receive fixed-dose ARNI therapy. Although generic products typically generate lower revenue per prescription than originator brands, the resulting expansion in treated patient volumes and long-term therapy utilization can partially offset price reductions and create incremental market opportunities.

• In January 2023, Glenmark Pharmaceuticals launched Sacu V (sacubitril + valsartan) in India specifically as a more affordable treatment option for patients with heart failure, highlighting how affordable generic participation can broaden treatment access and support prescription-volume expansion in emerging markets.

MARKET CHALLENGES

Adverse-Effects Concerns and Patient Monitoring Requirements to Challenge Broader Therapy Adoption

The need to manage treatment-related adverse effects and conduct regular patient monitoring is expected to remain a key challenge for the broader adoption of sacubitril/valsartan sodium drugs. Although sacubitril/valsartan has demonstrated significant clinical benefits in heart-failure management, treatment can be associated with hypotension, hyperkalemia, impaired renal function, dizziness, and angioedema, requiring careful patient selection and follow-up. These considerations are particularly important among elderly patients and individuals with renal impairment, diabetes, low baseline blood pressure, or concomitant use of medicines affecting potassium levels and renal function. The additional monitoring burden can complicate therapy optimization in outpatient settings and in healthcare systems with limited access to laboratory testing and specialist follow-up. Thus, despite the established clinical benefits of ARNI therapy, safety-management requirements and tolerability concerns may continue to create challenges for achieving broader and sustained sacubitril/valsartan utilization.

• In December 2025, the European Medicines Agency's post-authorization safety study record for Entresto was updated, highlighting continued real-world surveillance of specific safety events including angioedema, hypotension, hyperkalemia, and renal impairment among heart-failure patients receiving sacubitril/valsartan. This continued regulatory surveillance highlights the importance of safety monitoring as sacubitril/valsartan use expands across broader heart-failure populations.

Segmentation Analysis

By Product Type

Established Brand Leadership and High Value Realization to Support Originator/Innovator Product Segment Dominance

Based on product type, the market is categorized into originator/innovator products, branded generics, and unbranded generics.

The originator/innovator products segment dominated the market in 2025. This is primarily due to the long-standing commercial presence, strong physician familiarity, extensive clinical evidence, and broad reimbursement coverage associated with Novartis’ Entresto. This established position resulted in substantially higher prescription penetration compared to newer generic entrants. Moreover, premium pricing of the innovator product generated considerably greater revenue per prescription than generic alternatives, thereby increasing its contribution to overall market value. The originator continued to account for a significant proportion of full-year global value.

• For instance, in February 2026, Novartis reported that Entresto generated USD 7.748 billion in global sales during 2025, despite significant U.S. generic competition affecting the fourth quarter. The continued multibillion-dollar sales of Entresto even after the beginning of generic erosion highlight the substantial installed prescription base and value contribution retained by the originator product.

The unbranded generics segment is expected to grow at a CAGR of 18.79% over the forecast period.

To know how our report can help streamline your business, Speak to Analyst

By Disease Indication

Broad Clinical Indication and Guideline Adoption to Drive Heart Failure Segment Dominance

Based on disease indication, the market is segmented into heart failure, hypertension, and others.

In 2025, the heart failure segment accounted for the largest sacubitril valsartan sodium drugs market share owing to sacubitril/valsartan's well-established role as an ARNI therapy for chronic heart failure and its broad incorporation into guideline-directed medical therapy. A large population of patients with heart failure requires long-term pharmacological management to reduce cardiovascular mortality and recurrent hospitalization, creating a substantial and recurring prescription base for sacubitril/valsartan. Therefore, the combination of a larger addressable patient population, established guideline positioning, and chronic treatment requirements has concentrated the majority of sacubitril/valsartan demand within heart failure.

• For instance, in February 2021, Novartis AG announced the U.S. FDA's expanded indication for Entresto in adult patients with chronic heart failure, broadening treatment to include a wider range of patients with LVEF below normal.

The others segment is projected to grow at a CAGR of 10.99% during the forecast period.

By Formulation

Established Dose Architecture and Widespread Generic Development to Favor Film-Coated Tablets Segment’s Leadership

Based on formulation, the market is bifurcated into film-coated tablets and oral pellets/granules.

The film-coated tablets segment captured the largest market share in 2025. This formulation represents established and widely adopted dosage form for both the originator product and the majority of generic sacubitril/valsartan products. Film-coated tablets are commercially available across standardized dose strengths that support treatment initiation, dose escalation, and maintenance, allowing physicians to adjust therapy according to patient tolerability and clinical requirements. Therefore, established utilization and continued generic replication have supported the dominance of the segment.

• For instance, in April 2021, Zentiva completed a pivotal bioequivalence study comparing its sacubitril/valsartan film-coated tablets with Novartis' Entresto film-coated tablets. The study supported registration and future commercialization of its generic product in major European markets, illustrating how generic development has remained centered on the established film-coated tablet formulation.

The oral pellets/granules segment is projected to grow at a CAGR of 18.11% during the forecast period.

By Age Group

Large Adult Heart-Failure Population and Established Treatment Evidence to Support the Segment Dominance

Based on age group, the market is classified into pediatric and adults.

The adults segment dominated the market in 2025 due to the substantially higher burden of chronic heart failure among adult and elderly populations compared to pediatric patients. Increasing age, hypertension, coronary artery disease, diabetes, obesity, and other cardiovascular comorbidities contribute to a large adult population requiring long-term heart-failure treatment. Pharmaceutical companies have consequently focused a significant proportion of their commercialization and affordable generic-launch strategies on the adult patient population. As a result, the significantly larger adult treatment population translates into greater prescription volumes and market value.

• In January 2023, Lupin launched Valentas and Arnipin, its sacubitril/valsartan brands in India, specifically highlighting their use for reducing repeated hospitalization and cardiovascular death among adult patients with chronic heart failure.

The pediatric segment is projected to grow at a CAGR of 17.61% over the forecast period.

By Treatment Phase

Substantial Utilization of Drugs During Maintenance Phase of Treatment Enables the Segment’s Dominance

Based on treatment phase, the market is segmented into treatment initiation, dose titration, and maintenance therapy.

The maintenance therapy segment dominated the market as sacubitril/valsartan is primarily used for the long-term management of chronic heart failure rather than for short-duration treatment. Treatment initiation and dose titration generally represent relatively brief periods during which physicians establish tolerability and progressively optimize the patient's dose. Consequently, each patient generates considerably more tablet consumption during the maintenance period than during initiation or titration. Therefore, the combination of chronic disease management, prolonged treatment duration, and repeated daily dosing results in majority of cumulative drug consumption and revenue being generated during maintenance therapy.

• For instance, in January 2023, Glenmark Pharmaceuticals launched Sacu V in India for chronic heart failure and stated that the therapy is to be taken twice daily under a doctor's prescription. The company launched three dose levels—50 mg, 100 mg, and 200 mg—supporting dose adjustment as patients progress toward sustained therapy. The recurring twice-daily use in chronic heart failure highlights why cumulative drug consumption is concentrated in the maintenance phase.

The dose titration segment is projected to grow at a CAGR of 2.82% over the forecast period.

By Distribution Channel

Recurring Outpatient Prescriptions and Wider Accessibility to Support Drug Stores & Retail Pharmacies Dominance

Based on distribution channel, the market is segmented into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies.

The drug stores & retail pharmacies segment dominated the market owing to the outpatient and chronic nature of sacubitril/valsartan treatment. Sacubitril/valsartan is an oral medication that patients can self-administer at home following prescription and clinical evaluation. Once patients are stabilized on therapy, repeated monthly or periodic refills can be conveniently obtained through retail pharmacies, reducing the need for continued hospital-based dispensing. The extensive geographic reach of retail pharmacy networks also facilitates access for a considerably larger outpatient population, particularly in markets where heart-failure treatment is substantially financed through out-of-pocket spending. Thus, convenience, repeat prescription requirements, and increasing affordability support higher throughput through drug stores and retail pharmacies.

• May 2023, JB Pharma reported that after reducing the price of its sacubitril/valsartan brand Azmarda by 50% in December 2022, the product had returned to its pre-exclusivity monthly volume level by March 2023 despite increased generic competition. The volume response following greater affordability demonstrates the importance of recurring outpatient prescription demand, which supports high dispensing activity through accessible pharmacy channels.

The online pharmacies segment is projected to grow at a CAGR of 10.25% over the forecast period.

Sacubitril Valsartan Sodium Drugs Market Regional Outlook

By geography, the market is categorized into Europe, North America, Asia Pacific, Latin America, and Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

North America was valued at USD 4.23 billion in 2024 and maintained its leading position with a value of USD 3.83 billion in 2025. This is due to the large diagnosed heart-failure population, strong incorporation of ARNI therapy into guideline-directed care, and increasing treatment penetration, which continue to expand prescription volumes despite emerging generic price pressure.

U.S. Sacubitril Valsartan Sodium Drugs Market

Given North America's substantial contribution and the U.S. dominance in the region, the U.S. market is estimated at around USD 1.20 billion in 2026, accounting for roughly 18.68% of the global market sales.

Europe

Europe is projected to grow at 1.42% over the forecast period. Market growth in the European region is supported by continued adoption of guideline-directed heart-failure therapy, established reimbursement systems, and expansion of sacubitril/valsartan across broader patient groups, resulting in sustained ARNI utilization.

U.K. Sacubitril Valsartan Sodium Drugs Market

The U.K. market is estimated at USD 0.44 billion in 2026, accounting for roughly 6.88% of the global market.

Germany Sacubitril Valsartan Sodium Drugs Market

Germany's market is projected to reach approximately USD 0.33 billion in 2026, equivalent to around 5.12% of the global market.

Asia Pacific

Asia Pacific is estimated to reach USD 2.63 billion in 2026 and secure the third-largest position in the market. The market is expanding owing to large cardiovascular patient population, rising diagnosis and treatment rates, additional hypertension utilization in certain countries, and increasing availability of affordable branded generics.

Japan Sacubitril Valsartan Sodium Drugs Market

The Japanese market in 2026 is estimated at around USD 0.49 billion, accounting for approximately 7.67% of the global market.

China Sacubitril Valsartan Sodium Drugs Market

China's market is projected to be among the largest worldwide, with 2026 revenues estimated at around USD 1.02 billion, accounting for approximately 15.99% of global sales.

India Sacubitril Valsartan Sodium Drugs Market

The Indian market in 2026 is estimated at around USD 0.34 billion, accounting for roughly 5.33% of global revenue.

Latin America and Middle East & Africa

Latin America is expected to witness moderate growth in this market during the forecast period. The market in Latin America is estimated to reach a valuation of USD 0.32 billion in 2026. This growth is being supported by the high unmet cardiovascular disease burden, improving access to advanced heart-failure therapies, and initiatives targeting underserved populations, which are increasing the addressable patient base. In Middle East & Africa, the GCC is set to reach USD 0.11 billion in 2026.

South Africa Sacubitril Valsartan Sodium Drugs Market

The South African market is projected to reach approximately USD 0.05 billion by 2026, accounting for roughly 0.72% of global revenue.

COMPETITIVE LANDSCAPE

Key Industry Players

Focus on Generic Product Launches by Key Players to Intensify Market Competition

The sacubitril/valsartan sodium drugs market has a moderately consolidated but rapidly evolving competitive structure, with Novartis AG historically holding a significant market share through its originator product, Entresto. However, the competitive landscape is increasingly shifting with the entry of generic manufacturers such as Lupin Limited, Zydus Lifesciences Limited, Laurus Labs Limited, and Alembic Pharmaceuticals Limited. The leading market position of established companies is attributed to strong product recognition, extensive regulatory approvals, established distribution networks, large-scale manufacturing capabilities, and increasing investments in affordable generic formulations. The growing number of generic approvals and launches is expected to increase competition and gradually redistribute market share from the originator toward multiple generic manufacturers.

• For instance, in August 2025, MSN Pharmaceuticals launched its generic Sacubitril and Valsartan Tablets in the U.S. for reducing the risk of cardiovascular death and hospitalization in adults with chronic heart failure and reduced ejection fraction. The launch followed a multi-year regulatory and patent-litigation process and was aimed at expanding access to cost-effective cardiovascular medicines. The commercial entry of such generic products is expected to increase price competition and strengthen the presence of generic manufacturers in one of the largest markets globally.

The increasing competitive pressure is already affecting the market position of the originator. Other notable players in the global market include Alkem Laboratories Limited and Torrent Pharmaceuticals Limited. These companies are expected to prioritize regulatory approvals, competitive pricing, geographic expansion, product launches, and strengthening of distribution networks to enhance their positions during the forecast period for the market.

LIST OF KEY SACUBITRIL VALSARTAN SODIUM DRUGS COMPANIES PROFILED

• Novartis AG (Switzerland)
• Alkem Laboratories Limited (India)
• Biocon Limited (India)
• Torrent Pharmaceuticals Limited (India)
• Zydus Lifesciences Limited (India)
• Lupin Limited (India)
• Laurus Labs Limited (India)
• Alembic Pharmaceuticals Limited (India)
• Reddy’s Laboratories Limited (India)
• Macleods Pharmaceuticals Limited (India)
• Crystal Pharmaceutical (Suzhou) Co., Ltd. (China)
• Hetero Labs Limited (India)
• MSN Laboratories Private Limited (India)
• Glenmark Pharmaceuticals Limited (India)
• Somerset Therapeutics, LLC (U.S.)

KEY INDUSTRY DEVELOPMENTS

• March 2026: Krka expanded its cardiovascular portfolio with Valkubit (sacubitril/valsartan) and secured marketing authorizations for the product. Valkubit is intended for the treatment of patients with different forms of chronic heart failure. The development expands Krka's presence in cardiovascular generic drugs and increases the availability of sacubitril/valsartan-based therapies across its target markets.
• January 2026: Pharmascience Canada launched pms-SACUBITRIL-VALSARTAN, comprising sacubitril and valsartan film-coated tablets, in Canada. The product was made available in bottles of 60 and 180 tablets and blister packs containing 60 tablets. The launch expands the availability of generic sacubitril/valsartan therapies in Canada and strengthens Pharmascience's presence in the country's cardiovascular drugs market.
• November 2025: Biocon Limited announced that its Generics business recorded strong traction from recently launched formulations, including Sacubitril + Valsartan, across key markets. The product formed part of the company's expanding portfolio of complex generic formulations and contributed to improved momentum in its Generics business. The development broadens Biocon's participation in the cardiovascular drugs segment and strengthens the availability of generic sacubitril/valsartan across international markets.
• October 2025: Sandoz Canada launched Sandoz Sacubitril-Valsartan, an affordable generic alternative to Entresto, for the treatment of heart failure with reduced ejection fraction. The product was approved for the indications of the reference medicine and was introduced as part of Sandoz's expanding cardiovascular portfolio.
• August 2025: MSN Pharmaceuticals launched its generic Sacubitril + Valsartan Tablets in the U.S. for adult patients with chronic heart failure and reduced ejection fraction. The product is used to reduce the risk of cardiovascular death and hospitalization associated with heart failure. The launch expands access to affordable sacubitril/valsartan treatment in the U.S. and increases generic competition in the country's heart-failure therapeutics market.

REPORT COVERAGE

The sacubitril/valsartan sodium drugs market report provides market size estimates and forecasts for all key segments covered in the study. The market outlook also evaluates the key drivers, restraints, opportunities, challenges, and emerging trends expected to influence market growth during the forecast period. The report further analyzes the market by product type, disease indication, formulation, age group, treatment phase, and distribution channel. In addition, the report presents a comprehensive market analysis and a detailed competitive landscape covering estimated market shares, originator and generic product portfolios, regulatory approvals, patent and loss-of-exclusivity developments, pricing and generic competition, geographic presence, recent product launches, business expansion initiatives, and profiles of key market participants.

Request for Customization   to gain extensive market insights.

Report Scope & Segmentation

Research Methodology

1. Bottom Up Approaches

Approach 1:  Revenues and Market Share of Major Players

• Collection of sacubitril/valsartan-specific revenues from company annual reports, SEC/exchange filings, earnings releases, investor presentations, product disclosures, and regulatory filings.
• Identification of revenues attributable to Entresto and generic sacubitril/valsartan products marketed by Novartis, Lupin, Alkem Laboratories, Biocon, Zydus Lifesciences, Laurus Labs, Alembic Pharmaceuticals, Dr. Reddy’s Laboratories, Macleods Pharmaceuticals, Hetero Labs, MSN Laboratories, Glenmark Pharmaceuticals, and other relevant manufacturers.
• Segregation of market revenues across originator/innovator products, branded generics, and unbranded generics to determine the commercial structure of the market.
• Adjustment of reported revenues to manufacturer/product-owner net revenue, excluding distributor margins, pharmacy mark-ups, repackaging value, taxes, and other non-manufacturer components.
• Allocation of revenues for companies with broader cardiovascular portfolios using product-specific sales, prescription volumes, geographic presence, launch timing, and market availability.
• Elimination of duplicate revenues arising from licensing, distribution, contract manufacturing, API supply, and repackaging arrangements between market participants.
• Estimation of company-level market shares and reconciliation with country-level prescription trends, generic penetration, product launches, and regional demand indicators.
• Triangulation of company-revenue estimates with patient-level and product-level approaches to derive the final global and regional market values.

Approach 2: Country-level Treated Patient Volume × Regimen × Manufacturer Net Price

• Identification of the diagnosed, eligible, and treated heart-failure population across major countries included within the study.
• Inclusion of hypertension-related utilization only in countries where sacubitril/valsartan is approved and commercially used for the indication.
• Segmentation of treated patients by adult and pediatric populations and by treatment phase, including initiation, dose titration, and maintenance therapy.
• Estimation of sacubitril/valsartan utilization based on recommended dosing frequency, dose strengths, tablets consumed per day, treatment duration, adherence, persistence, and discontinuation rates.
• Assessment of country-specific treatment patterns across 24/26 mg, 49/51 mg, and 97/103 mg equivalent dose strengths, along with alternative formulations where commercially available.
• Collection and normalization of manufacturer/OEM net prices for originator, branded-generic, and unbranded-generic products across individual countries.
• Calculation of annual manufacturer revenue by multiplying treated patients × annual drug consumption × manufacturer net price, adjusted for the applicable originator/generic product mix.
• Aggregation of country-level values into regional and global estimates, followed by reconciliation with reported company sales and prescription-utilization indicators.

Approach 3:  Disease Epidemiology and Treatment-Adoption Model

• Assessment of heart-failure prevalence, incidence, diagnosis rates, treated-patient population, and disease severity across the major countries included in the study.
• Evaluation of the eligible population based on heart-failure phenotype, left ventricular ejection fraction, clinical characteristics, contraindications, renal function, blood pressure, and other treatment-selection factors.
• Estimation of the proportion of diagnosed patients receiving guideline-directed medical therapy and the share eligible for angiotensin receptor-neprilysin inhibitor (ARNI) treatment.
• Modelling of treatment switching from ACE inhibitors and angiotensin receptor blockers to sacubitril/valsartan, based on clinical guidelines, physician adoption, access, reimbursement, and generic availability.
• Assessment of therapy initiation, dose escalation, maintenance, adherence, persistence, discontinuation, and mortality to calculate the annual continuously treated population.
• Evaluation of hypertension-related patient opportunity in selected markets where the combination carries an approved hypertension indication.
• Conversion of treated-patient volumes into annual sacubitril/valsartan consumption using regimen, treatment duration, dosage strength, and manufacturer-level net price assumptions.
• Cross-validation of epidemiology-based market values with company revenues, prescription trends, and country-level pharmaceutical utilization

2. Top Down Approaches

Approach 1: Analysis of Parent Markets and Credible Secondary Sources and Institutional Data

• Analysis of parent markets such as cardiovascular drugs to estimate the proportion accounted by sacubitril valsartan sodium drugs in that market.
• Validation of market assumptions using information from the U.S. FDA, EMA/European Commission, PMDA/MHLW, NMPA/CDE, CDSCO/DCGI, TGA, WHO, OECD, World Bank, and national health authorities.
• Analysis of recommendations and treatment pathways published by leading cardiology and heart-failure societies, including guideline-directed use of ARNI therapy.
• Review of company annual reports, SEC/exchange filings, investor presentations, earnings disclosures, product labels, regulatory approvals, launch announcements, and manufacturing disclosures.
• Assessment of national and regional prescription, reimbursement, formulary, pricing, and patient-access data to validate treatment penetration and manufacturer net-price assumptions.
• Evaluation of patent and exclusivity information, ANDA/generic approvals, regulatory databases, patent litigation, and loss-of-exclusivity timelines to determine generic-entry patterns.
• Use of public procurement records, tenders, hospital formularies, pharmacy reimbursement databases, and prescription-utilization information where available.
• Review of credible epidemiological publications and institutional cardiovascular datasets for cross-validation of the eligible and treated heart-failure population.
• Third-party market research reports are excluded as primary evidence, with final assumptions based predominantly on primary, regulatory, institutional, and publicly verifiable sources.

3. List of Key Sources

• Annual reports, SEC/exchange filings, earnings releases, investor presentations, and product-specific company disclosures
• Company websites, product portfolios, press releases, licensing agreements, partnerships, product launches, and manufacturing updates
• S. FDA, including Drugs@FDA, Orange Book, ANDA approvals, prescribing information, and first-generic approvals
• European Medicines Agency (EMA) and European Commission regulatory databases
• PMDA and Ministry of Health, Labour and Welfare, Japan
• NMPA/CDE, China
• CDSCO/DCGI, India
• Therapeutic Goods Administration (TGA), Australia
• WHO, OECD, World Bank, national cardiovascular registries, and national health statistics agencies
• American Heart Association, American College of Cardiology, European Society of Cardiology, Heart Failure Association, and other cardiovascular societies
• National reimbursement agencies, formularies, medicine-price databases, and health-technology-assessment organizations
• Government procurement portals, hospital tender databases, and publicly available pharmaceutical purchasing records
• Patent, exclusivity, generic-approval, and litigation databases
• Peer-reviewed clinical studies, treatment guidelines, clinical trial registries, and epidemiological publications
• Prescription, utilization, reimbursement, and pharmacy-dispensing datasets where publicly accessible.

4. Primary Interviews

Supply Side Interviews: 60%

• Key Respondents:
  • Originator and generic sacubitril/valsartan manufacturers
  • Business development and alliance-management executives
  • Commercial, marketing, product, and sales managers
  • Regulatory affairs and market-access professionals
  • Manufacturing, quality assurance, and supply-chain executives
  • API and finished-dosage-form manufacturers
  • Pharmaceutical distributors, wholesalers, and tender-participation teams
  • Contract manufacturing and licensing partners

Demand Side Interviews: 40%

• Key Respondents:
  • Cardiologists and heart-failure specialists
  • Internal medicine physicians and primary-care physicians
  • Hospital pharmacists and pharmacy directors
  • Hospital procurement and formulary-management professionals
  • Retail and community pharmacy stakeholders
  • Payers, reimbursement specialists, and health-technology-assessment experts
  • Public-health and cardiovascular-program administrators
  • Clinical pharmacologists and treatment-pathway experts